HVTN 502 (STEP study)

Status:Stopped Early
Principal Investigator(s):
Objective:To continue evaluating the safety and begin evaluating the efficacy of an investigational HIV vaccine.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionMRKAd5 HIV-1 gag/pol/nef trivalent vaccine
Mode of DeliveryIntramuscular
Trial Sponsors: NIAID, SAAVI
Start Date
End Date
December 31, 2004
September 18, 2007
Age range: 18 Years ↔ 45 Years
Population:Cisgender Men, Cisgender Women